Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 11,408 matching trials from the live ClinicalTrials.gov search.

Filters: Seattle, Washington Clear all

Conditions: Graft Versus Host Disease
Interventions: tocilizumab, laboratory biomarker analysis, quality-of-life assessment; Biological · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2016
U.S. locations: 5
States / cities: Phoenix, Arizona • Rochester, Minnesota • Nashville, Tennessee + 2 more

Conditions: Lung Cancer
Interventions: cisplatin, etoposide, tirapazamine, radiation therapy; Drug · Radiation
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 87
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 56 more

Conditions: HIV Infections
Interventions: ATV, Ritonavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 91 Days to 21 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2014
U.S. locations: 32
States / cities: Birmingham, Alabama • Alhambra, California • La Jolla, California + 23 more

Conditions: Metastatic Pancreatic Cancer
Interventions: Albumin-bound paclitaxel (ABI-007), Gemcitabine; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 861 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 90
States / cities: Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 71 more

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: MDX, Placebo; Drug
Lead sponsor: Alcobra Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 283 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 36
States / cities: Dothan, Alabama • Los Alamitos, California • Newport Beach, California + 32 more

Conditions: Acute Lymphoblastic Leukemia
Interventions: Bortezomib, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, Methotrexate, Vincristine, Triple IT Therapy; Drug
Lead sponsor: Therapeutic Advances in Childhood Leukemia Consortium; Other
Eligibility: 1 Year to 21 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 20
States / cities: Duarte, California • Long Beach, California • Los Angeles, California + 16 more

Conditions: Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies, Heart Diseases
Interventions: acoramidis, Placebo Oral Tablet; Drug
Lead sponsor: Eidos Therapeutics, a BridgeBio company; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 632 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 40
States / cities: Los Angeles, California • Santa Monica, California • Aurora, Colorado + 32 more

Conditions: Alcohol Use, Tobacco Use, Substance Use, Sexual Health
Interventions: Journey of Transformation-Native Youth Health Leadership Program curriculum; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 13 Years to 16 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Alcohol Abuse, Alcohol Dependence, Substance Abuse, Substance Dependence
Interventions: Motivational Enhancement Therapy, Education; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Glioblastoma Multiforme, Glioblastoma, GBM, Grade IV Astrocytoma, Glioma, Brain Cancer, Brain Tumor
Interventions: Dendritic cell immunotherapy; Drug
Lead sponsor: Northwest Biotherapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 71
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Castro Valley, California + 56 more

Conditions: Overactive Bladder
Interventions: Vibegron; Drug
Lead sponsor: Urovant Sciences GmbH; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 31
States / cities: Huntsville, Alabama • Lincoln, California • Los Angeles, California + 26 more

Conditions: Depressive Disorder, Major
Interventions: CP-316,311, Placebo, Sertraline; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 2
States / cities: Bellevue, Washington • Seattle, Washington

Conditions: AML, Adult
Interventions: APG 2575 ramp up arm; Drug
Lead sponsor: Ascentage Pharma Group Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Los Angeles, California • Charlotte, North Carolina • Winston-Salem, North Carolina + 2 more

Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions: Cytology Specimen Collection Procedure; Other
Lead sponsor: National Cancer Institute LAO; Other
Eligibility: 2 Months and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 140
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Arroyo Grande, California + 95 more

Conditions: Breast Cancer
Interventions: Persona: Primary care doctor, Persona: Breast cancer survivor, Communication Style: Direct, Communication Style: Indirect; Other
Lead sponsor: University of Washington; Other
Eligibility: 40 Years to 74 Years · Female only
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Coronary Occlusion
Interventions: coraFlex Catheter, coraForce Catheter, coraCross Catheter; Device
Lead sponsor: ReFlow Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Pediatric Cancer, Animal-Assisted Activities
Interventions: Therapy Dog Visit; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 5 Years to 17 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Osteoporosis, Postmenopausal
Interventions: TVB-009, Prolia®; Combination Product
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 60 Years to 90 Years · Female only
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 20
States / cities: Phoenix, Arizona • Tucson, Arizona • San Diego, California + 17 more

Conditions: Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Carcinoma, Ovarian Carcinosarcoma, Ovarian High Grade Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions: Bevacizumab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib; Biological · Procedure · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 676
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 458 more

Conditions: HIV-1 Infection
Interventions: ISL, DOR, DOR/ISL, Placebo to ISL, Placebo to DOR; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: Not listed
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 15 more

Conditions: Septic Shock, Inflammation, Glucose Homeostasis, Organ Dysfunction, Health-related Quality of Life
Interventions: Exenatide, Exenatide vehicle; Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 1 Month to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Abdominal Pain, Isolated Extremity Fracture, Pain, Pediatrics
Interventions: Ketamine hydrochloride, Morphine sulphate; Drug
Lead sponsor: Columbia University; Other
Eligibility: 6 Years to 17 Years
Enrollment: 1,010 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 8
States / cities: Los Angeles, California • Sacramento, California • Wilmington, Delaware + 5 more

Conditions: Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Systemic Anaplastic Large Cell Lymphoma, Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell
Interventions: Soquelitinib, Belinostat, Pralatrexate; Drug
Lead sponsor: Corvus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 24
States / cities: Duarte, California • Irvine, California • San Francisco, California + 19 more

Conditions: Healthy Subject
Interventions: Dietary Intervention, Dual X-ray Absorptiometry, Questionnaire Administration; Dietary Supplement · Procedure · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Tocilizumab for Chronic Graft-versus-Host Disease Treatment

S0004: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-stage Small Cell Lung Cancer

Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents

Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas

The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD

Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)

Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy

Journey of Transformation Curriculum for Native American Adolescents

Efficacy Trial of Warrior Check-Up

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia

Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder

A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)

Collection and Storage of Tissue and Blood Samples From Patients With Cancer

Design of Chatbot Persona for Breast Cancer Screening Outreach Among Black Women

Single-Arm Study Evaluating Use of the CORA Catheters for the Crossing of Coronary Chronic Total Occlusions

Helping Improve Pediatric Patient Outcomes

A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)

Pharmacology of Exenatide in Pediatric Sepsis

Morphine or Ketamine for Analgesia

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Effects of Alternative Healthy Eating Index-Based Diet on Inflammatory Markers and Breast Density in Healthy Participants